MHRA Cuts Nasal Decongestant Spray Limit to 5 Days

Published Date: 02 May 2026

The MHRA has cut the recommended use of xylometazoline and oxymetazoline nasal sprays to five days over rebound congestion risks.

Read Full News

Latest News

Early MRI Detects Brain Injury in Newborns With HIE

MRI performed during therapeutic hypothermia accurately identifies the pattern and severity of brain injury in newborns with hypoxic-ischemic encephalopathy.

Syncope or Fall? A Practical Risk Approach in Older Adults

Experts say witness accounts, ECG findings, and simple risk scores can help clinicians distinguish syncope from a mechanical fall.

Evommune Scraps Eczema Drug After Trial Miss, Shares Plunge

Evommune said on Tuesday it will not advance its experimental skin disease ⁠drug after it failed to meet the main goal in a mid-stage trial, ⁠sending its shares down 24% in...

Sparsentan Achieves Rapid, Sustained Response in Nephropathy

In patients with immunoglobulin A nephropathy treated according to current standards of care, sparsentan use is linked to a rapid and sustained reduction in proteinuria, a real-world study finds.

Does Humor Have a Place in Modern Medicine?

Medical anecdotes show how wit, empathy, and communication can shape clinical encounters, offering a glimpse into human experiences that unfold beyond diagnosis and treatment.

Genetic Testing Before Prescribing: Routine or Selective?

Pharmacogenetic testing can inform medication choice and adverse effect risk, while questions remain about implementation, data storage, and access in routine care.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Todays Updates

UK Lawmakers Reject Bid to Legalise Assisted Dying

British lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...

Liberalized Cannabis Policies May Increase Substance Use

In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

Can Response-Adapted Surgery Improve Outcomes in HNSCC?

Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

Latest News

MRI performed during therapeutic hypothermia accurately identifies the pattern and severity of brain injury in newborns with hypoxic-ischemic encephalopathy.

Experts say witness accounts, ECG findings, and simple risk scores can help clinicians distinguish syncope from a mechanical fall.

Evommune said on Tuesday it will not advance its experimental skin disease ⁠drug after it failed to meet the main goal in a mid-stage trial, ⁠sending its shares down 24% in...

In patients with immunoglobulin A nephropathy treated according to current standards of care, sparsentan use is linked to a rapid and sustained reduction in proteinuria, a real-world study finds.

Medical anecdotes show how wit, empathy, and communication can shape clinical encounters, offering a glimpse into human experiences that unfold beyond diagnosis and treatment.

Pharmacogenetic testing can inform medication choice and adverse effect risk, while questions remain about implementation, data storage, and access in routine care.

News All Time

Urine Culture Can Speed Urosepsis Pathogen Detection

In suspected urosepsis, urine culture matched the pathogen found in blood culture in 54.6% of episodes while delivering results faster, potentially enabling earlier targeted antimicrobial therapy.

MRSA Prevention Program Cuts Hospital-Onset Bacteremia

An educational quality improvement program significantly reduces hospital-onset methicillin-resistant Staphylococcus aureus bacteremia events across all the participating hospital units.

Ex-Health Minister: Time to Rebuild Mental Healthcare

Mental health campaigner Sir Norman Lamb sets out the four questions he thinks the NHS must answer to fix mental healthcare.

We Might Have Been Wrong About How the Immune System Ages

A rare immune cell linked to cancer resistance increases in the very old, suggesting the immune system actively adapts to extreme longevity.

SMC Backs Gene Therapy for Metachromatic Leukodystrophy

In children with metachromatic leukodystrophy, early gene therapy preserved motor function and survival in long-term follow-up.

Pharvaris' Genetic Disorder Drug Meets Main Goal in Late-stage Trial

Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting ⁠the main goal of a late-stage...
HTTP error: 503HTTP error: 503HTTP error: 503

1 in 5 Patients With Bacteremia Have Skin Involvement

Skin involvement is common in neutropenic patients with a Pseudomonas aeruginosa bloodstream infection, a study suggests.
HTTP error: 503HTTP error: 503

e-Cigarettes May Increase Risk for RA or SLE

Current e-cigarette users face a higher risk of developing incident rheumatoid arthritis or systemic lupus erythematosus than nonusers, a study finds.
HTTP error: 503

5 Things Doctors Should Know About Medical AI Regulation

Federal and state regulators are drawing new boundaries around medical AI, from how the tools are vetted to who bears responsibility when they fail.

Salmonella Cases Top 500 in Outbreak Linked to Imported Eggs

The UKHSA says the outbreak now spans three genetically distinct Salmonella clusters, but the risk to the public remains low.

Recommended News For You

Disparities in use of MRI to detect prostate cancer: Race and location may influence testing

What is Mohs micrographic surgery? 8 FAQs about Mohs

Cancer detection recovered following pandemic disruptions

AI-based liquid biopsy shows promise for detecting brain cancer

Research exposes far-reaching toll of financial hardship on patients with cancer

Ultrasonography of hepatocellular carcinoma: From diagnosis to prognosis

X-ray and radar technology combined to reduce cancer screening risks

Recommended Articles For You

Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine 

Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care 

Emerging Therapies Using Combination Radiopharmaceutical Platforms for Sequential Tumor Targeting 

Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

5.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

1.

Tumor Ecological Stability and Disease Course Evolution

2.

Intrapancreatic Fat, Pancreatitis, and Cancer: Role of Cancer-Associated Fibroblasts

3.

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment

4.

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment

5.

Critical Care Updates on Hematopoietic Dysfunction During Prolonged Critical Illness

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

2.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks

3.

Comprehensive Update on Hematology

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

5.

Efficient Management of First line ALK-rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot